Kornimate/medical-research-clean huggingface dataset:
intrinsic respiratory rate assessment during mechanical ventilation to accelerate spontaneous breathing and extubation

Conditions: Reverse Triggering; Patient Ventilator Dyssynchrony

Summary: the goal of this study is to identify patients with reverse triggering who's the potential to breath spontaneously is hidden because of the ventilator management strategy by performing a simple 30sec-test with includes reducing the support from the ventilator. the findings will provide clear advice to doctors on how to better care for these patients. this will be a pilot randomized clinical trial including 70 adult patients (aimed at equal number of men and woman) sedated and under controlled ventilation having reverse triggering. the study will be conducted in two icus: 1) st. michael's hospital, toronto canada and 2) toronto western hospital, toronto, canada.

the objective of this study is to investigate the impact of assessing intrinsic respiratory rate in mechanically ventilated patients with reverse triggering on the facilitation of transition to spontaneous breathing and successful extubation. patients will be excluded if under current use of continuous neuromuscular blocking agent or severe metabolic acidosis (ph\<7.25 at the time of study procedure. patients will be screened every morning from 8:00 am to 9:00 am all the patients under controlled ventilation to detect the presence of reverse triggering by looking at the screen on the ventilator (2-5 min observation). the research team (research mds, physiotherapists and respiratory therapists) is very well trained at detecting reverse triggering. patients will then be randomized to standard of care or intervention using a deferred consent model. * control group: standard care. * intervention group: the intervention is a simple brief test as follows: with the ventilator set with the patient clinical settings, it will be performed an up to 30sec-long or two inspiratory effort and expiratory occlusion maneuver on the ventilator and/or switch the patient to pressure support for up to 30sec-long to assess the presence of intrinsic respiratory rate. if an intrinsic respiratory rate ≥8 breaths per minute is present and p/f ratio is ≥150 it will be performed a 5-minute "test" in pressure support ventilation with the pressure support level to match the clinical setting of the patient. if the patient tolerates well 5 minutes in pressure support (see criteria below) the clinical team will be informed: - it will be indicated that the patient tolerated 5 min of pressure support ventilation and suggest to the clinicians and physician in charge to transition the patient to pressure support ventilation plus suggest reducing sedation.

Eligibility criteria:
inclusion criteria: * adult patients (aimed at equal number of men and woman) sedated and under controlled ventilation having reverse triggering. exclusion criteria: * under current use of continuous neuromuscular blocking agent or severe metabolic acidosis (ph\<7.25) at the time of study procedure.

Keywords: mechanical ventilation dyssynchrony reverse triggering intensive care unit
light therapy for internet gaming disorder

Conditions: Internet Gaming Disorder; Light Therapy

Summary: this project aims to investigate (1) the efficacy of light therapy on internet gaming disorder (igd); (2) the underlying neural mechanisms of such efficacy


Eligibility criteria:
inclusion criteria: 1. the 5th edition of diagnostic and statistical manual of mental disorders (dsm-5 ) recommended diagnosis of internet gaming disorder; 2. the scores of the young-internet addiction test ≥ 50; 3. playing internet games ≥15 h/week for ≥1 year exclusion criteria: 1. current or history of psychiatric or neurological illness; 2. current or history of use of illegal substances and other addictions; 3. current use of psychotropic medications ; 4. any history of head trauma, presence of metal in the body or other contraindication to functional mri scanning; 5. photosensitivity disorders, such as systemic lupus erythematosus and chronic actinic dermatitis.
effects of hepatic fibrosis on hepatic steatosis using the ultrasound attenuation imaging in chronic hepatitis b

Conditions: Hepatic Steatosis; Hepatic Fibrosis; Chronic Hepatitis b

Summary: the investigator aimed to prospectively study the effect of the hepatic fibrosis on quantifying hepatic steatosis using ultrasound attenuation imaging (ati value) in patients with chronic hepatitis b.

chronic hepatitis b virus (hbv) infection has been reported to be associated with the prevalence of non-alcoholic fatty liver disease (nafld). prior studies demonstrate that concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis b. therefore, quantification of hepatic steatosis and fibrosis in chronic hepatitis b patient has important clinical significance in active surveillance. ultrasound imaging provides reliable noninvasive quantification of hepatic steatosis and fibrosis. attenuation imaging (ati) reflects hepatic steatosis and 2d-shear wave elastography reflects hepatic fibrosis. the potential interaction between of the hepatic fibrosis and the hepatic steatosis in chronic hepatitis b is not fully understood. the investigator investigated the effect of the hepatic fibrosis on quantifying hepatic steatosis using ultrasound attenuation imaging (ati value) in patients with chronic hepatitis b.

Eligibility criteria:
inclusion criteria: * chronic hepatitis b patients * who is scheduled for pathological exam such as liver biopsy or surgery, that can quantify hepatic steatosis and hepatic fibrosis * who submitted informed consent exclusion criteria: * who underwent liver transplantation or right hemihepatectomy * huge hepatic mass or numerous cysts in right hepatic lobe, who is not eligible for measuring ultrasound attenuation imaging and fibroscan * high bleeding risk patients

Keywords: ultrasound attenuation imaging
pain impact assessment of the relational touch during arterial puncture in icu (torrea)

Conditions: Pain

Summary: study objective is to assess the interest of the relational touch before an arterial puncture to reduce pain on patient in intensive care unit.


Eligibility criteria:
inclusion criteria: * admission in intensive care unit * communicating patient (able to rate their pain on a numerical scale) * need for a radial arterial puncture for conducting blood tests, apart for the emergency * non-opposition of the patient exclusion criteria: * age under 18 * tetraplegic patient or having a sensitivity disorder on the limb to be punctured * no radial pulse perception

Keywords: intensive care arterial puncture cross-over relational touch pain
study evaluating local susceptibility patterns associated with tigecycline in comparison to other antibiotics

Conditions: Infection

Summary: various bacterial organisms will be tested in order to compile information regarding the effectiveness of tigecycline against certain bacteria seen in local communities.

this is a prospective, microbiologic in vitro evaluation which will study the susceptibility of tigecycline in disk diffusion on clinical bacterial isolates collected from inpatients and outpatients. fourteen hospital centers participated in the program. in vitro efficacy of tigecycline will be determined through the in vitro disk diffusion activity, using fda breakpoints.

Eligibility criteria:
inclusion criteria: any protocol-specified microorganism isolated from the samples collected from hospitalized patients and outpatients

Keywords: susceptibility of tigecycline drug resistance, bacterial
follow-up of critical covid-19 patients

Conditions: COVID19; ARDS; AKI; Circulatory Failure; Coagulation Disorder; Inflammatory Response

Summary: the study will follow covid-19 patients who required intensive care after 3-6 months and one year after discharge from the icu with functional level as well as organ function to assess recovery after covid-19. blood and urine will be collected for biobanking.

the study will follow covid-19 patients who required intensive care at uppsala university hospital and were included in the uppsala covid-19 biobank. the patients will be contacted after three to six months for a first follow-up with assessment of functional level in activities of daily life, psychiatric symptoms, neurological symptoms and working capacity as well as specific organ functions. the organ functions will include circulation, respiration, coagulation, immune function and kidney function. in addition, blood and urine will be collected for biobanking.

Eligibility criteria:
inclusion criteria: * pcr-verified covid-19 * treated in icu exclusion criteria: * pregnant of breastfeeding

Keywords: corona virus acute kidney injury sars vasopressor respiratory failure
a double-blind, paralleled study comparing efficacy/safety of solifenacin to tolterodine in overactive bladder patients

Conditions: Urinary Bladder, Overactive

Summary: to evaluate the efficacy and safety of solifenacin succinate (vesicare) 5mg od in subjects with overactive bladder compared to tolterodine wmg, bid


Eligibility criteria:
inclusion criteria: * patients willing and able to complete the micturition diary correctly * patients experiencing frequency of micturition as verified in the diary * patients experiencing significant post void residual volume * oab symptoms including urinary frequency, urgency or urge incontinence for 3 months or more. exclusion criteria: * significant post void residual volume * patients with indwelling catheters or practicing intermittent self- catheterization * known or suspected hypersensitivity to solifenacin succinate or other anticholinergics or lactose

Keywords: solifenacin overactive bladder urinary incontinence treatment outcomes vesicare
human mass balance of [14c]hmpl-523 in healthy adult male chinese subjects

Conditions: Imumune Thrombocytopenia(ITP) Human Mass Balance

Summary: to evaluate the absorption, metabolism and excretion of hmpl-523 in healthy male chinese subjects following multiple oral doses of hmpl-523 tablets followed by a single oral dose of \[14c\]hmpl-523 suspension

a single-center, non-randomized, open-label, human mass balance, phase 1 study to evaluate the absorption, metabolism and excretion following multiple oral doses of hmpl-523 tablets, followed by a single oral dose of 300 mg/150 µci \[14c\]hmpl-523 suspension in healthy adult male chinese subjects.

Eligibility criteria:
inclusion criteria: 1. subjects who have voluntarily participated in the study and signed the informed consent form with good compliance; 2. healthy male subjects aged 18-40 years (inclusive); 3. subjects weighing ≥ 50 kg 4. subjects in good health status exclusion criteria: 1. subjects with a history of gastrointestinal surgery, renal surgery, cholecystectomy and other procedures that in the judgment of the investigator may affect drug absorption or excretion 2. hypersensitivity to the investigational product and its excipients 3. subjects with diseases affecting the absorption, distribution, metabolism and excretion of oral drugs, 4. subjects with fear of needles, hemophobia, difficulty collecting venous blood, or special requirements for diet, who cannot comply with uniform diet 5. subjects who are abnormal with clinical significance for c-reactive protein or positive for coronavirus nucleic acid detection in coronavirus infection screening 6. subjects who have participated in another clinical trial of other drugs and have received such investigational product within 3 months prior to the first dose 7. having any other diseases or conditions that may affect the normal performance of the study or the evaluation of the study data, or having other conditions that are not suitable for the study, as judged by investigators
exhaled breath: a novel technique for rapid diagnosis of respiratory diseases and infections

Conditions: Pulmonary Disease; Critical Illness

Summary: this study aims to use mass spectrometry techniques to analyze exhaled patient breath in non-covid icu-admitted patients requiring ventilation for a rapid and accurate early detection of pulmonary diseases and inflammatory markers.

the major aim of this observational study is to validate the new technique, orbitrap and matrix-assisted laser desorption ionization (maldi) mass spectrometry, to sample and analyze exhaled patient breath that may be then used in non-intensive care unit (icu) environments where rapid virus or other respiratory pathogen detection is of great utility. the icu permits the direct measure of ventilator-dependent patients with known pulmonary disease (by sputum, chest x-ray, and/or bronchial lavage analysis) together with a simple, pure, and concentrated breath sample (expired air via ventilator tubing) for analysis. sub-aim 1: run patient samples on orbitrap \& maldi. proteins in the samples will be captured and analyzed by orbitrap and maldi mass spectrometry. selected proteins will be enzymatically digested into peptides and correlations to existing peptides from previous proteomic studies of exhaled breath condensates (ebc) will be examined. candidate virus \& bacterial proteins, as well as other cellular and biomarkers, will be cataloged. sub-aim 2: correlate collected analyzed sample collection during hospitalization with other hospital data that may have been collected for clinical reasons by the clinical care team, at or around the study time period (+/- 3 days), concerning for the laboratory diagnosis of respiratory disease.

Eligibility criteria:
inclusion criteria: * non-covid-19 adult consented patients (\>18yo) on ventilatory support in the icu at ohsu exclusion criteria: * patients with "severe respiratory distress" as defined by arterial po2 of \<60 mmhg on maximal fio2 \& optimal ventilator settings * patient with severe hemodynamic instability as defined by (a) receiving iv infusion of 2 or more pressors or inotropic medications (levophed, vasopressin, phenylephrine, or epinephrine) \& (b) map of \<60 mmhg or sb \<80 mmhg

Keywords: ventillator critical care pulmonary disease inflammatory biomarkers
pregnancy related inappropriate sinus tachycardia

Conditions: Inappropriate Sinus Tachycardia; Pregnancy Related

Summary: a feasibility study into the exploration of possible mechanisms underlying inappropriate sinus tachycardia (ist) syndrome in pregnancy.

this is a non-interventional, physiological study which will explore the feasibility of examining autonomic function and related haemodynamic variables in pregnant women with and without inappropriate sinus tachycardia, with the aim of providing scope for future research. sinus tachycardia (normal heart rhythm but fast heart rate) is common and usually related to an obvious cause (e.g. exercise such a running or cycling) and doesn't cause any untoward symptoms. in rare cases however, sinus tachycardia can occur without an obvious cause (i.e. it is inappropriate to the situation) and can cause distressing symptoms such as palpitations, dizziness and breathlessness at rest or with minimal exertion. this syndrome of inappropriate sinus tachycardia is poorly understood and can be difficult to manage; especially when the affected individual is pregnant. in order to understand the condition better and improve care pathways we aim to measure various features of the cardiovascular system in pregnant women with and without ist.

Eligibility criteria:
inclusion criteria: * aged 18-45 years of age * able to give written informed consent and willing to participate * the participant falls into one of the below categories: i. pregnant women with ist ii. pregnant women without ist exclusion criteria: * obesity (bmi \> 29.9) * current or recent (within last 3 months) smoker * known medical condition likely to affect hrv (other than ist in relevant groups) * previous history of hypertensive disorders in pregnancy * lack of written informed consent

Keywords: inappropriate sinus tachycardia pregnancy related ist
exposure, d-cycloserine enhancement, and functional magnetic resonance imaging (fmri) in snake phobics

Conditions: Specific Phobia

Summary: the aim of the present study is to determine whether people receiving d-cycloserine and exposure therapy show different brain reactions to symptom provocation compared to people receiving placebo and exposure therapy.

d-cycloserine (dcs) is a partial n-methyl-d-aspartate (nmda) receptor agonist that may improve or accelerate extinction learning. we will randomly assign people with snake phobia to receive dcs or placebo, and then provide all participants with exposure therapy. we will examine whether people receiving dcs and vs. placebo show different brain reactions to symptom provocation before and after exposure therapy.

Eligibility criteria:
inclusion criteria: * primary diagnosis of specific phobia (snakes) exclusion criteria: * history of psychosis, obsessive-compulsive disorder, or mania * recent substance abuse or suicidality * previous receipt of study treatments
safety study of infant formula with partially hydrolized whey

Conditions: Growth Failure

Summary: the study will be a randomized, double-blind, prospective trial. newborn infants (enrollment age 0-14 days) will be assigned randomly to receive one of two products, provided in identical packages except for the lid color. neither the investigators nor the parents will know which product the infant is receiving. the infants will be monitored at study enrollment, and at 4, 8, and 12 weeks of age. there will be two study groups, each receiving one of the following formulas: 1. the new partially hydrolyzed whey formula (nf) - materna cow's milk infant formula containing partially hydrolyzed whey protein, produced and packaged by materna laboratories, maabarot. 2. the currently marketed partially hydrolyzed whey formula (cf) - nan ha, produced by nestlé. in order to maintain blinding, the nan ha will be repacked in packaging identical to the materna product, except for the lid color

the study will be a randomized, double-blind, prospective trial. newborn infants (enrollment age 0-14 days) will be assigned randomly to receive one of two products, provided in identical packages except for the lid color. neither the investigators nor the parents will know which product the infant is receiving. the infants will be monitored at study enrollment, and at 4, 8, and 12 weeks of age. there will be two study groups, each receiving one of the following formulas: 1. the new partially hydrolyzed whey formula (nf) - materna cow's milk infant formula containing partially hydrolyzed whey protein, produced and packaged by materna laboratories, maabarot. 2. the currently marketed partially hydrolyzed whey formula (cf) - nan ha, produced by nestlé. in order to maintain blinding, the nan ha will be repacked in packaging identical to the materna product, except for the lid color

Eligibility criteria:
inclusion criteria: healthy term neonates whose mothers are not able or choose not to breastfeed for medical, social, or personal reasons, will be recruited exclusion criteria: * twins * premature or low birth weight (\< 2500 g). * chromosomal abnormalities or congenital malformations. * jaundice of more than 12 mg% and/or phototherapy. * treatment with antibiotics or other drugs during the last three days or more prior to the commencement of the study.

Keywords: infant formula, milk allergy, hydrolized whey
phase 3 study of snf472 for calciphylaxis

Conditions: Calciphylaxis; Calcific Uremic Arteriolopathy

Summary: the primary objectives are to assess the efficacy, safety, and tolerability of snf472 compared to placebo when added to background care for the treatment of calciphylaxis (cua).

the formation and growth of calcified deposits in arterioles and other small blood vessels appears to be fundamental to the development of cua especially in end stage renal disease patients. this phase 3 double-blind, randomized, placebo-controlled study is designed to assess the effect of snf472 when added to background care to improve wound healing, as evaluated using bates-jensen wound assessment tool (bwat) scoring and pain as reported by the subject using a vas scale. the study consists of a double-blind, randomized, placebo controlled period of 12 weeks followed by an open-label period of 12 weeks.. .

Eligibility criteria:
inclusion criteria: * female or male subjects, 18 years of age or older * receiving maintenance hd in a clinical setting for at least 2 weeks prior to screening * clinical diagnosis of cua by the investigator including ≥1 cua lesion with ulceration of the epithelial surface * cua wound-related pain shown by a pain vas score ≥50 out of 100 * primary lesion that can be clearly photographed for the purpose of protocol-specified wound healing assessments. * willing and able to understand and sign the informed consent form and willing to comply with all aspects of the protocol exclusion criteria: * history of treatment with bisphosphonates within 3 months of baseline * severely ill subjects without a reasonable expectation of survival for at least 6 months * subjects with a scheduled parathyroidectomy during the study period * expectation for kidney transplant within the next 6 months based on investigator assessment or identification of a known living donor * pregnant or trying to become pregnant, currently breastfeeding, or of childbearing potential (including perimenopausal women who have had a menstrual period within one year) and not willing to comply with protocol required contraception criteria * significant noncompliance with dialysis * history of active malignancy within the last year with the exception of localized basal cell or squamous cell carcinoma * clinically significant illness other than cua within 30 days * participation in an investigational study and receipt of an investigational drug or investigational use of a licensed drug within 30 days prior to screening. * history or presence of active alcoholism or drug abuse as determined by the investigator within 6 months * mental impairment, current significant psychiatric disease, or other conditions or circumstances that would make the subject unlikely to complete the study or comply with the study procedures. * subjects whose cua lesions exhibit significant improvement, in the opinion of the investigator, between the first and second screening visit

Keywords: calciphylaxis calcific uremic arteriolopathy wound esrd
study evaluating cci-779 in active rheumatoid arthritis on concomitant methotrexate therapy

Conditions: Rheumatoid Arthritis

Summary: the primary objective of this study is to compare the therapeutic response and safety of 3 oral dose levels of cci-779, with placebo in subjects with active rheumatoid arthritis (ra) who have been receiving stable doses of methotrexate (mtx) for at least 8 weeks.


Eligibility criteria:
inclusion criteria: * meet american college of rheumatology (acr) criteria for ra * have active ra consisting of ≥ 6 swollen and ≥ 6 painful joints * acr functional class i-iii exclusion criteria * at screening the subject's prior medications are reviewed. (prior history of disease-modifying antirheumatic drug (dmard) use is recorded, including the start and stop dates of the most recently taken dmards) * significant concurrent medical diseases * abnormal chest radiograph, including findings consistent with interstitial pneumonitis, granulomatous disease, or pleural effusion and/or infiltration